Humacyte (HUMA) Price & Analysis

Compare

1,478 Followers

HUMA Stock Chart & Stats

$1.28

-$0.19(-4.01%)

At close: Jan 08 4:00 PM EST

$1.28

-$0.19(-4.01%)

Day’s Range― - ―

52-Week Range$1.09 - $6.77

Previous CloseN/A

Volume1.64M

Average Volume (3M)5.18M

Market Cap

$239.71M

Enterprise Value$306.40M

Total Cash (Recent Filing)$19.49M

Total Debt (Recent Filing)$29.82M

Price to Earnings (P/E)―

Beta2.57

Next Earnings

Mar 26, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding187,271,320

10 Day Avg. Volume5,921,172

30 Day Avg. Volume5,176,492

Financial Highlights & Ratios

PEG Ratio-0.23

Price to Book (P/B)-11.36

Price to Sales (P/S)0.00

P/FCF Ratio-6.00

Enterprise Value/Market Cap1.28

Enterprise Value/Revenue34.82

Enterprise Value/Gross Profit350.98

Enterprise Value/Ebitda-16.18

Forecast

1Y Price Target

$5.40

Price Target Upside321.88% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.34

Revenue Forecast (FY)$2.67M

Bulls Say, Bears Say

Bulls Say

Clinical MomentumHumacyte’s VEITH performance showcased clinical momentum for the Symvess (ATEV) platform.

Market ExpansionThe number of value analysis committee (VAC) approvals for Symvess nearly doubled, indicating strong potential for future sales growth.

Regenerative BiologyNew data validated its regenerative biology, strengthening its role in high-acuity trauma.

Bears Say

Humacyte News

Humacyte announces presentations at VEITHsymposium on ATEV results

Humacyte (HUMA) announced highlights of five podium presentations on the Company’s acellular tissue engineered vessel, ATEV, made yesterday...

6d ago

HUMA

Humacyte price target lowered to $11 from $14 at Benchmark

Benchmark analyst Bruce Jackson lowered the firm’s price target on Humacyte (HUMA) to $11 from $14 and keeps...

13d ago

HUMA

Humacyte reports Q3 EPS (11c), consensus (15c)

Reports Q3 revenue $753,000, consensus $922,830. “During the third quarter of 2025 we continued to execute on our...

14d ago

HUMA

Humacyte announces presentation of two-year results from V007 Phase 3 trial

Humacyte (HUMA) announced the presentation of positive two-year results from the V007 Phase 3 clinical trial of the...

16d ago

HUMA

Humacyte announces publication of new data on Symvess

Humacyte (HUMA) announced the publication of a new study comparing clinical outcomes of Symvess to autologous vein in...

27d ago

HUMA

Humacyte’s Promising Growth in Vascular Therapy Market Justifies Buy Rating

Analyst Josh Jennings of TD Cowen maintained a Buy rating on Humacyte, retaining the price target of $3.50....

1d ago

HUMA

Positive Growth Prospects and Financial Stability Drive Buy Rating for Humacyte

H.C. Wainwright analyst Swayampakula Ramakanth has reiterated their bullish stance on HUMA stock, giving a Buy rating yesterday....

13d ago

HUMA

Humacyte Reports Q3 2025 Financial Results and Pipeline Progress

Humacyte ( ($HUMA) ) has released its Q3 earnings. Here is a breakdown of the information Humacyte presented...

13d ago

HUMA

Humacyte’s Earnings Call Highlights Growth and Challenges

Humacyte (($HUMA)) has held its Q3 earnings call. Read on for the main highlights of the call. The...

14d ago

HUMA

Humacyte’s Promising Growth and Strategic Collaborations Earn a Buy Rating

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Humacyte, with a...

14d ago

HUMA

HUMA Upcoming Earnings Report: What to Expect?

Humacyte (HUMA) is scheduled to report 3rd quarter earnings on 11/07/2025. Regarding Q3 estimates, Wall Street analysts expect...

21d ago

HUMA

Humacyte’s Phase 3 Trial: A New Era for Renal Disease Treatment?

Humacyte (($HUMA)) announced an update on their ongoing clinical study. Humacyte (HUMA) has initiated a Phase 3 clinical...

30d ago

HUMA

Humacyte price target lowered to $6 from $7 at BTIG

BTIG lowered the firm’s price target on Humacyte (HUMA) to $6 from $7 and keeps a Buy rating...

1M ago

HUMA

Humacyte Announces $60M Stock and Warrants Offering

Humacyte ( ($HUMA) ) has provided an update. On October 6, 2025, Humacyte, Inc. entered into a securities...

2M ago

HUMA

HUMA FAQ

What was Humacyte’s price range in the past 12 months?

Humacyte lowest stock price was $1.09 and its highest was $6.77 in the past 12 months.

What is Humacyte’s market cap?

Humacyte’s market cap is $239.71M.

When is Humacyte’s upcoming earnings report date?

Humacyte’s upcoming earnings report date is Mar 26, 2026 which is in 120 days.

How were Humacyte’s earnings last quarter?

Humacyte released its earnings results on Nov 12, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.151 by $0.041.

Is Humacyte overvalued?

According to Wall Street analysts Humacyte’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Humacyte pay dividends?

Humacyte does not currently pay dividends.

What is Humacyte’s EPS estimate?

Humacyte’s EPS estimate is -0.13.

How many shares outstanding does Humacyte have?

Humacyte has 187,271,320 shares outstanding.

What happened to Humacyte’s price movement after its last earnings report?

Humacyte reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.151. Following the earnings report the stock price went down -2.344%.

Which hedge fund is a major shareholder of Humacyte?

Currently, no hedge funds are holding shares in HUMA

Humacyte Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-20.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte (HUMA) Earnings & Revenues

Historic Earnings Reports

HUMA Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted several positive developments, including a significant increase in product sales, expansion of hospital approvals, positive long-term results for Symvess, a strong financial performance with reduced net loss, successful fundraising, and expansion of intellectual property. However, challenges remain with increased administrative expenses and some resistance in the hospital VAC process due to budget constraints.View all HUMA earnings summaries

HUMA Stock 12 Month Forecast

Average Price Target

$5.40

▲(321.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,2.3876923076923076,3.105384615384615,3.8230769230769233,4.5407692307692304,5.258461538461539,5.976153846153847,6.693846153846154,7.411538461538462,8.12923076923077,8.846923076923076,9.564615384615385,10.282307692307693,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,1.956923076923077,2.243846153846154,2.5307692307692307,2.8176923076923077,3.1046153846153848,3.3915384615384614,3.6784615384615384,3.9653846153846155,4.252307692307692,4.53923076923077,4.826153846153846,5.113076923076923,{"y":5.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,1.7723076923076921,1.8746153846153846,1.9769230769230768,2.079230769230769,2.1815384615384614,2.2838461538461536,2.386153846153846,2.4884615384615385,2.5907692307692307,2.693076923076923,2.7953846153846156,2.8976923076923073,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.05,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >